Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06658899 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of CRD-4730 in CPVT
A Phase 2 study of Catecholaminergic Polymorphic Ventricular Tachycardia, sponsored by Cardurion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 9
- Study locations
NCT06658899 is a Phase 2 study of Catecholaminergic Polymorphic Ventricular Tachycardia that is actively recruiting participants, run by Cardurion Pharmaceuticals. The registered enrollment target is 12 participants. The trial reports 9 study locations across 9 states.
The verdict
NCT06658899, a Phase 2 study of Catecholaminergic Polymorphic Ventricular Tachycardia, is actively recruiting participants, sponsored by Cardurion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Participants with CPVT will complete a 3-period, randomized 3-sequence study. Each participant will be randomized to one of the 3 sequences in which they will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CRD-4730
Study Locations (9)
California
- Cardurion Investigative Site - San Francisco
North Carolina
- Cardurion Investigative Site - Morrisville
Texas
- Cardurion Investigative Site - Houston
Wisconsin
- Cardurion Investigative Site - Madison
British Columbia
- Cardurion Investigative Site - Vancouver
Other
- Cardurion Investigative Site - Saint-Herblain
Pavia
- Cardurion Investigative Site - Pavia
North Holland
- Cardurion Investigative Site - Amsterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06658899
The ClinicalTrials.gov registry entry for NCT06658899 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardurion Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Catecholaminergic Polymorphic Ventricular Tachycardia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06658899 reports 9 study locations spanning 9 distinct geographic areas - top geographies include California, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT06658899 about?
NCT06658899 is a clinical study titled "A Phase 2 Study of CRD-4730 in CPVT". This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPV...
What is the current status of trial NCT06658899?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2025-12-01. Estimated completion is 2027-04.
What conditions does trial NCT06658899 study?
This clinical trial studies the following conditions: Catecholaminergic Polymorphic Ventricular Tachycardia.
What interventions are being tested in trial NCT06658899?
The interventions under investigation include: Placebo (DRUG), CRD-4730 (DRUG).
Who is sponsoring clinical trial NCT06658899?
This trial is sponsored by Cardurion Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06658899 being conducted?
This trial has 9 study locations across California, North Carolina, Texas, Wisconsin, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Catecholaminergic Polymorphic Ventricular Tachycardia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.